Q1 2025 Management View CEO Dr. Ron Kurtz highlighted that Q1 2025 revenue was impacted by a weakened premium intraocular lens (IOL) market, disruptions from sequential product launches by competitors ...

Each year, ophthalmologists perform thousands of cataract surgeries, yet only a small percentage of patients choose premium IOLs, despite the lenses offering significantly better vision outcomes ...

RxSight faces revenue decline and rising competition in the IOL market. Click here to find out why I am neutral on RXST stock.

RxSight (RXST) stock plunged 28% as the MedTech firm cut full-year guidance and issued disappointing early Q1 results, citing market challenges. Read more here.

Given RxSight’s (RXST) more significant installed base of surgeons and practices, we now must navigate headwinds affecting ...

PRINCETON, N.J., April 14, 2025 /PRNewswire/ -- Hoot Health, Inc., a leader in specialty medical marketing automation, today announced the launch of Hoot Ophthalmology, a breakthrough platform ...